Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27514647.
- Also identified by DOI 10.1111/add.13521 and PMC identifier 5233591.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
New hepatitis C virus (HCV) treatments with very high cure rates can reduce the burden of liver disease in the population and could reduce HCV transmission. There are no ethical grounds for denying these treatments to people with severe or moderate liver disease who inject drugs (PWID). The cost-effectiveness of providing HCV treatment for PWID who have early stages of liver disease remains to be demonstrated.
Medical subject headings
- Hepatitis C
- Substance Abuse, Intravenous
- Time-to-Treatment